Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence-Reference-Cited by-同舟云学术

Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence

Published:2023-05 Issue:3 Volume:75 Page:
ISSN:2724-6051
Container-title:Minerva Urology and Nephrology
language:
Short-container-title:Minerva Urol Nephrol

Author:

PICCINELLI Mattia L.,PANUNZIO Andrea,TAPPERO Stefano,CANO GARCIA Cristina,BARLETTA Francesco,INCESU Reha-Baris,TIAN Zhe,LUZZAGO Stefano,MISTRETTA Francesco A.,FERRO Matteo,SAAD Fred,SHARIAT Shahrokh F.,TILKI Derya,BRIGANTI Alberto,CHUN Felix K.,TERRONE Carlo,ANTONELLI Alessandro,DE COBELLI Ottavio,MUSI Gennaro,KARAKIEWICZ Pierre I.

Publisher

Edizioni Minerva Medica

Subject

Urology,Nephrology

Link

https://www.minervamedica.it/pdf.php?cod=R19Y2023N03A0319

Reference19 articles.

1. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

2. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

3. Everest CW. EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study clinicaltrials.gov. 2010 [Internet]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01120249?term=everest&cond=renal+cell+carcinoma&draw=2&rank=1 [cited 2023, Mar 7].

4. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

5. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal cell carcinoma with non-clear cell histologies: all the same peas in one pod?;Minerva Urology and Nephrology;2023-08